MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$42,683K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from public offering
Proceeds from maturities of inve...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of investment securiti...
Net loss
Accounts receivable, net
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-09-30
2025-06-30
Net loss
-36,765
-61,140
Depreciation expense
27
57
Stock-based compensation expense
5,794
11,021
Accretion of discount on investment securities
2,311
2,997
Amortization of right-of-use operating lease assets
72
175
Gain on investment in former related party
227
27
Receivable from former related party
0
-807
Unbilled receivable from former related party
0
0
Accounts receivable, net
4,961
39
Prepaid expenses and other current assets
35
1,321
Other assets
-89
-476
Accounts payable, accrued expenses and operating lease liabilities
3,004
1,589
Deferred revenue
4,758
-123
Deferred revenue - former related party
0
0
Net cash used in operating activities
-30,555
-51,522
Capital expenditures
5
70
Purchases of investment securities
279,841
100,437
Proceeds from maturities of investment securities
78,571
141,746
Net cash used in investing activities
-201,275
41,239
Proceeds from public offering
272,268
-
Payment of issuance costs in connection with public offering
172
-
Proceeds from exercise of stock options
2,230
599
Proceeds from issuance of common stock under espp
187
129
Proceeds from exercise of pre-funded warrants
0
1
Proceeds from private placement
0
0
Payment of issuance costs in connection with private placement
0
0
Net cash provided by financing activities
274,513
729
Increase/(decrease) in cash, cash equivalents and restricted cash
42,683
-9,554
Cash and cash equivalents at beginning of period
23,022
-
Cash and cash equivalents at end of period
56,151
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from public
offering
$272,268K
Proceeds from exercise of
stock options
$2,230K
Proceeds from issuance of
common stock under espp
$187K
Net cash provided by
financing activities
$274,513K
Canceled cashflow
$172K
Increase/(decrease) in cash, cash
equivalents and restricted...
$42,683K
Canceled cashflow
$231,830K
Payment of issuance
costs in connection...
$172K
Proceeds from maturities
of investment...
$78,571K
Stock-based compensation
expense
$5,794K
Deferred revenue
$4,758K
Accounts payable,
accrued expenses and...
$3,004K
Other assets
-$89K
Amortization of right-of-use
operating lease assets
$72K
Depreciation expense
$27K
Net cash used in
investing activities
-$201,275K
Net cash used in
operating activities
-$30,555K
Canceled cashflow
$78,571K
Canceled cashflow
$13,744K
Purchases of investment
securities
$279,841K
Net loss
-$36,765K
Capital expenditures
$5K
Accounts receivable, net
$4,961K
Accretion of discount on
investment securities
$2,311K
Gain on investment in
former related party
$227K
Prepaid expenses and
other current assets
$35K
Buy us a coffee
Dianthus Therapeutics, Inc. DE (DNTH)
Dianthus Therapeutics, Inc. DE (DNTH)